Commercialisation Of Biotechnology Research
Download Commercialisation Of Biotechnology Research full books in PDF, epub, and Kindle. Read online free Commercialisation Of Biotechnology Research ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Oliver Uecke |
| Publisher | : Gabler Verlag |
| Total Pages | : 0 |
| Release | : 2012-04-21 |
| Genre | : Business & Economics |
| ISBN | : 9783834941336 |
Biotechnology is considered as a key technology of the 21st century with the potential to offer technological solutions for global health and resource-based problems. Oliver Uecke analyses how early stages of the innovation process in biotechnology can be effectively managed, with the aim to transfer an innovation from academia to industry. A mixed method approach is applied with a multiple case study approach to identify characteristics for effective management and with the method of discrete choice experiments/best-worst scaling to estimate the importance of these characteristics. This study adds to existing research by identifying a group of five important characteristics that should be considered in the early stages of the innovation process, compared to a group of four characteristics that are less important. The results have implications for policy, directors and the management of research institutes and universities, entrepreneurs, TTO manager and other stakeholders involved in technology transfer.
| Author | : Craig Shimasaki |
| Publisher | : Academic Press |
| Total Pages | : 489 |
| Release | : 2014-04-08 |
| Genre | : Medical |
| ISBN | : 0124047475 |
As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a 'how-to' for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. - Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars - Case studies are interspersed throughout each chapter to support key concepts and best practices. - Enhanced by use of numerous detailed graphics, tables and flow charts
| Author | : |
| Publisher | : |
| Total Pages | : 28 |
| Release | : 1984 |
| Genre | : Biotechnology industries |
| ISBN | : |
| Author | : Krishna R. Dronamraju |
| Publisher | : World Scientific |
| Total Pages | : 485 |
| Release | : 2008 |
| Genre | : Business & Economics |
| ISBN | : 9812775013 |
The principal message of this book is that thermodynamics and statistical mechanics will benefit from replacing the unfortunate, misleading and mysterious term "entropy" with a more familiar, meaningful and appropriate term such as information, missing information or uncertainty. This replacement would facilitate the interpretation of the "driving force" of many processes in terms of informational changes and dispel the mystery that has always enshrouded entropy. It has been 140 years since Clausius coined the term "entropy"; almost 50 years since Shannon developed the mathematical theory of "information"--Subsequently renamed "entropy." In this book, the author advocates replacing "entropy" by "information," a term that has become widely used in many branches of science. The author also takes a new and bold approach to thermodynamics and statistical mechanics. Information is used not only as a tool for predicting distributions but as the fundamental cornerstone concept of thermodynamics, held until now by the term "entropy." The topics covered include the fundamentals of probability and information theory; the general concept of information as well as the particular concept of information as applied in thermodynamics; the re-derivation of the Sackur-Tetrode equation for the entropy of an ideal gas from purely informational arguments; the fundamental formalism of statistical mechanics; and many examples of simple processes the "driving force" for which is analyzed in terms of information.
| Author | : Timothy A. Caulfield |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 224 |
| Release | : 1999-12-31 |
| Genre | : Business & Economics |
| ISBN | : 9780306462870 |
The rapid advances made in genetic research and technology over the last few decades have led to a host of important discoveries that have allowed for the detection (and hopefully soon the treatment) of a number of genetic conditions and diseases. Not surprisingly, these advances have also raised numerous ethical concerns about how result ing technologies will be implemented, and the impact they will have on different com munities. One particular concern is the enormous costs involved in conducting genetic research and the fact that the private sector has become heavily involved; the desire to commercialize the results and technology derived from genetic research is considered problematic. In September 1998, the Second International Conference on DNA Sampling, titled "The Commercialization of Genetic Research: Ethical, Legal and Policy Issues," was held of the conference, and of this book, was to in Edmonton, Alberta, Canada. The goal facilitate an interdisciplinary discussion of the legal, ethical, and policy implications arising from the commercialization of genetic research. We solicited contributions for the book from authors in fields as diverse as ethics, law, medicine, health policy, and the social sciences. The papers included, while based on presentations given at the conference, have been substantially expanded and enhanced by the commentary received and discussions held at the conference.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 231 |
| Release | : 2017-07-28 |
| Genre | : Science |
| ISBN | : 0309452058 |
Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously possible. What will the likely future products of biotechnology be over the next 5â€"10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology? Preparing for Future Products of Biotechnology analyzes the future landscape of biotechnology products and seeks to inform forthcoming policy making. This report identifies potential new risks and frameworks for risk assessment and areas in which the risks or lack of risks relating to the products of biotechnology are well understood.
| Author | : Craig D. Shimasaki |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 282 |
| Release | : 2009-09-18 |
| Genre | : Medical |
| ISBN | : 1441900640 |
My journey into this fascinating field of biotechnology started about 26 years ago at a small biotechnology company in South San Francisco called Genentech. I was very fortunate to work for the company that begat the biotech industry during its formative years. This experience established a solid foundation from which I could grow in both the science and business of biotechnology. After my fourth year of working on Oyster Point Boulevard, a close friend and colleague left Genentech to join a start-up biotechnology company. Later, he approached me to leave and join him in of all places – Oklahoma. He persisted for at least a year before I seriously considered his proposal. After listening to their plans, the opportunity suddenly became more and more intriguing. Finally, I took the plunge and joined this ent- preneurial team in cofounding and growing a start-up biotechnology company. Making that fateful decision to leave the security of a larger company was extremely difficult, but it turned out to be the beginning of an entrepreneurial career that forever changed how I viewed the biotechnology industry. Since that time, I have been fortunate to have cofounded two other biotechnology com- nies and even participated in taking one of them public. During my career in these start-ups, I held a variety of positions, from directing the science, operations, regulatory, and marketing components, to subsequently becoming CEO.
| Author | : Melinda E. Cooper |
| Publisher | : University of Washington Press |
| Total Pages | : 233 |
| Release | : 2011-02-01 |
| Genre | : Science |
| ISBN | : 0295990317 |
Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.
| Author | : Shreefal S. Mehta |
| Publisher | : Cambridge University Press |
| Total Pages | : 449 |
| Release | : 2008-04-24 |
| Genre | : Technology & Engineering |
| ISBN | : 110739421X |
Successful product design and development requires the ability to take a concept and translate the technology into useful, patentable, commercial products. This book guides the reader through the practical aspects of the commercialization process of drug, diagnostic and device biomedical technology including market analysis, product development, intellectual property and regulatory constraints. Key issues are highlighted at each stage in the process, and case studies are used to provide practical examples. The book will provide a sound road map for those involved in the biotechnology industry to effectively plan the commercialization of profitable regulated medical products. It will also be suitable for a capstone design course in engineering and biotechnology, providing the student with the business acumen skills involved in product development.
| Author | : Gordon M. Binder |
| Publisher | : Harvard Business Review Press |
| Total Pages | : 326 |
| Release | : 2008 |
| Genre | : Biography & Autobiography |
| ISBN | : |
Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage.
